Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/14740338.2021.1962284 http://scihub22266oqcxt.onion/10.1080/14740338.2021.1962284 34338121!ä!34338121 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 253.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Expert+Opin+Drug+Saf 2021 ; 20 (11): 1299-1307 Nephropedia Template TP {{tp|p=34338121|t=2021. Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness |pdf=|usr=}}{{34338121}} gab.com Text Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness JO: Expert Opin Drug Saf http://www.kidney.de/pget.php?&tw=1&pmid=34338121 #FOAvip INTRODUCTION: Remdesivir is a nucleoside analog that inhibits viral RNA replication by blocking RNA-dependent RNA polymerase. First developed and tested during the Ebola epidemic, repurposed, and gained prominence during the Coronavirus disease 19 (COVID-19) pandemic. Based on data from three major trials, remdesivir became the first and only medication to obtain approval from the Food and Drug Administration (FDA) to treat patients hospitalized with COVID-19 disease. AREAS COVERED: The purpose of the article is to review available preclinical, clinical, and post-marketing data to assess the safety and efficacy of remdesivir in the treatment of COVID-19 patients. We performed a comprehensive literature review of articles published on remdesivir until January 2021. EXPERT OPINION: The substantial evidence of its effectiveness in a few trials together with the favorable safety profile makes remdesivir a primary therapeutic candidate for treatment in adult and pediatric patients who are hospitalized with COVID-19 and requiring oxygen supplementation. While remdesivir does not improve mortality, it has been shown to reduce the recovery time and increase the odds for clinical improvement, specifically in patients with early presentation and moderate COVID-19 disease. Remdesivir is well tolerated and has an acceptable safety profile in the pediatric and adult populations. Twit Text FOAVip Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness ????Expert Opin Drug Saf http://www.kidney.de/pget.php?&tw=1&pmid=34338121 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34338121 #FOAvip English Wikipedia <ref>{{Cite pmid|34338121}}</ref> Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness #MMPMID34338121 Mechineni A; Kassab H; Manickam R Expert Opin Drug Saf 2021[Nov]; 20 (11): 1299-1307 PMID34338121show ga INTRODUCTION: Remdesivir is a nucleoside analog that inhibits viral RNA replication by blocking RNA-dependent RNA polymerase. First developed and tested during the Ebola epidemic, repurposed, and gained prominence during the Coronavirus disease 19 (COVID-19) pandemic. Based on data from three major trials, remdesivir became the first and only medication to obtain approval from the Food and Drug Administration (FDA) to treat patients hospitalized with COVID-19 disease. AREAS COVERED: The purpose of the article is to review available preclinical, clinical, and post-marketing data to assess the safety and efficacy of remdesivir in the treatment of COVID-19 patients. We performed a comprehensive literature review of articles published on remdesivir until January 2021. EXPERT OPINION: The substantial evidence of its effectiveness in a few trials together with the favorable safety profile makes remdesivir a primary therapeutic candidate for treatment in adult and pediatric patients who are hospitalized with COVID-19 and requiring oxygen supplementation. While remdesivir does not improve mortality, it has been shown to reduce the recovery time and increase the odds for clinical improvement, specifically in patients with early presentation and moderate COVID-19 disease. Remdesivir is well tolerated and has an acceptable safety profile in the pediatric and adult populations. |*COVID-19 Drug Treatment[MESH] |Adenosine Monophosphate/adverse effects/*analogs & derivatives/therapeutic use[MESH] |Alanine/adverse effects/*analogs & derivatives/therapeutic use[MESH] |Animals[MESH] |Antiviral Agents/adverse effects/*therapeutic use[MESH] |COVID-19/diagnosis/virology[MESH] |Humans[MESH] |SARS-CoV-2/*drug effects/growth & development/pathogenicity[MESH] |Treatment Outcome[MESH]Remdesivir for the treatment of COVID 19: review of the pharmacologica(epmc).pdf DeepDyve Pubget Overpricing